Literature DB >> 2184902

Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor.

E J Clutterbuck1, C J Sanderson.   

Abstract

The effect of a panel of recombinant human (rh) cytokines on the generation of human eosinophil precursors was assessed using a two-step culture technique. Normal human bone marrow was preincubated with different cytokine combinations in liquid culture before assessment of the number of eosinophil progenitors, which give rise to eosinophil colony-forming units (CFU-Eo) on secondary semi-solid culture with either interleukin-5 (IL-5), IL-3, or granulocyte-macrophage colony-stimulating factor. rhIL-3 or rhGM-CSF, but not rhIL-5, increased the number of CFU-Eo. CFU-Eo production by rhIL-3 or rhGMCSF was maximal after 7 days' preincubation. Neither rhIL-1 or rhIL-6 acted on eosinophil precursors, either alone or in combination with rhIL-5, rhIL-3, or rhGM-CSF. A similar spectrum of activity of the cytokines was demonstrated whether rhIL-5, rhIL-3, or rhGM-CSF was used in the secondary cultures as the eosinophil CSF. However, rhIL-3 induced relatively more rhIL-5-responsive CFU-Eo than rhIL-3-responsive CFU-Eo, suggesting that rhIL-3 is pushing progenitors into an rhIL-5-responsive compartment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184902

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Regulation of eosinophil recruitment and allergic airway inflammation by heparan sulfate proteoglycan (HSPG) modifying enzymes.

Authors:  Xiao Na Ge; Idil Bastan; Sung Gil Ha; Yana G Greenberg; Jeffrey D Esko; Savita P Rao; P Sriramarao
Journal:  Exp Lung Res       Date:  2018-04-05       Impact factor: 2.459

2.  IL-3 up-regulates and activates human eosinophil CD32 and αMβ2 integrin causing degranulation.

Authors:  S Esnault; M W Johansson; E A Kelly; L Koenderman; D F Mosher; N N Jarjour
Journal:  Clin Exp Allergy       Date:  2017-01-23       Impact factor: 5.018

3.  Expression of interleukin-8 by lipopolysaccharide-stimulated bone marrow-derived mononuclear cells.

Authors:  C R Dibb; R M Strieter; M Burdick; S L Kunkel
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis.

Authors:  Christian Schwartz; Ralf Willebrand; Silke Huber; Rudolf A Rupec; Davina Wu; Richard Locksley; David Voehringer
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

Review 5.  Mepolizumab in eosinophilic disorders.

Authors:  J Pablo Abonia; Philip E Putnam
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

6.  Induction of lung eosinophilia and neutrophilia in guinea pigs following injection of sephadex beads.

Authors:  K Maghni; F Blanchette; P Sirois
Journal:  Inflammation       Date:  1993-10       Impact factor: 4.092

7.  Elevated IL-5 levels in pleural fluid of patients with paragonimiasis westermani.

Authors:  H Taniguchi; H Mukae; N Matsumoto; M Tokojima; S Katoh; S Matsukura; K Ogawa; S Kohno; Y Nawa
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

8.  Acute side effects of homologous interleukin-3 in rhesus monkeys.

Authors:  F C van Gils; A H Mulder; C van den Bos; H Burger; R W van Leen; G Wagemaker
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

Review 9.  Analysis of the immune system with transgenic mice: B cell development and lymphokines.

Authors:  A Iglesias
Journal:  Experientia       Date:  1991-09-15

10.  1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant.

Authors:  K A Yamaoka; N Miyasaka; G Inuo; I Saito; J P Kolb; K Fujita; S Kashiwazaki
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.